2017 – Time for a Bold R&D Initiative in Women’s Health

Despite NIH and FDA women's health policy initiatives previously described in this blog, the list of novel drugs approved by FDA in 2016 includes only one product for a woman-specific health indication. FDA granted accelerated approval in December 2016 for rucaparib (Rubraca™), a Clovis Oncology PARP inhibitor for ovarian cancer. Rubraca is indicated for patients [...]

2017 – Time for a Bold R&D Initiative in Women’s Health 2018-08-14T21:09:50+00:00
SUBMIT RFP